Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.79
ARAY's Cash to Debt is ranked higher than
54% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 6.28 vs. ARAY: 0.79 )
ARAY' s 10-Year Cash to Debt Range
Min: 0.79   Max: No Debt
Current: 0.79

Equity to Asset 0.20
ARAY's Equity to Asset is ranked lower than
58% of the 358 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. ARAY: 0.20 )
ARAY' s 10-Year Equity to Asset Range
Min: -0.65   Max: 0.69
Current: 0.2

-0.65
0.69
F-Score: 5
Z-Score: 0.73
M-Score: -2.74
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -25.53
ARAY's Operating margin (%) is ranked lower than
51% of the 363 Companies
in the Global Medical Devices industry.

( Industry Median: 6.75 vs. ARAY: -25.53 )
ARAY' s 10-Year Operating margin (%) Range
Min: -586.2   Max: 1.28
Current: -25.53

-586.2
1.28
Net-margin (%) -32.67
ARAY's Net-margin (%) is ranked lower than
52% of the 363 Companies
in the Global Medical Devices industry.

( Industry Median: 5.06 vs. ARAY: -32.67 )
ARAY' s 10-Year Net-margin (%) Range
Min: -584.5   Max: 2.56
Current: -32.67

-584.5
2.56
ROE (%) -96.62
ARAY's ROE (%) is ranked lower than
59% of the 363 Companies
in the Global Medical Devices industry.

( Industry Median: 5.79 vs. ARAY: -96.62 )
ARAY' s 10-Year ROE (%) Range
Min: -96.62   Max: 4.12
Current: -96.62

-96.62
4.12
ROA (%) -21.69
ARAY's ROA (%) is ranked higher than
50% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 3.38 vs. ARAY: -21.69 )
ARAY' s 10-Year ROA (%) Range
Min: -48.97   Max: 1.82
Current: -21.69

-48.97
1.82
ROC (Joel Greenblatt) (%) -199.58
ARAY's ROC (Joel Greenblatt) (%) is ranked lower than
52% of the 376 Companies
in the Global Medical Devices industry.

( Industry Median: 12.75 vs. ARAY: -199.58 )
ARAY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -199.58   Max: 13.24
Current: -199.58

-199.58
13.24
Revenue Growth (%) 5.40
ARAY's Revenue Growth (%) is ranked higher than
72% of the 278 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. ARAY: 5.40 )
ARAY' s 10-Year Revenue Growth (%) Range
Min: -7   Max: 133.5
Current: 5.4

-7
133.5
» ARAY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

ARAY Guru Trades in Q1 2013

Paul Tudor Jones 98,000 sh (New)
Chuck Royce 1,141,500 sh (New)
Steven Cohen 577,900 sh (+35.98%)
PRIMECAP Management 7,861,600 sh (+3.51%)
John Burbank 4,000,000 sh (unchged)
Jim Simons Sold Out
» More
Q2 2013

ARAY Guru Trades in Q2 2013

Chuck Royce 1,385,500 sh (+21.38%)
PRIMECAP Management 7,861,600 sh (unchged)
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
John Burbank 1,940,013 sh (-51.5%)
» More
Q3 2013

ARAY Guru Trades in Q3 2013

Steven Cohen 650,000 sh (New)
PRIMECAP Management 8,301,600 sh (+5.6%)
Chuck Royce 1,443,500 sh (+4.19%)
John Burbank Sold Out
» More
Q4 2013

ARAY Guru Trades in Q4 2013

Jim Simons 447,523 sh (New)
Steven Cohen 1,007,200 sh (+54.95%)
Chuck Royce 1,468,500 sh (+1.73%)
PRIMECAP Management 8,301,600 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ARAY

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2013-09-30 Sold Out 0.37%$5.41 - $7.3 $ 9.0143%0
John Burbank 2013-06-30 Reduce -51.5%0.38%$4.17 - $5.9 $ 9.0178%1940013
George Soros 2011-09-30 Sold Out 0.0018%$3.63 - $8.73 $ 9.0153%0
Jean-Marie Eveillard 2011-09-30 Sold Out 0.0011%$3.63 - $8.73 $ 9.0153%0
George Soros 2011-06-30 New Buy$6.72 - $9.49 $ 9.0111%16100
Jean-Marie Eveillard 2011-06-30 New Buy$6.72 - $9.49 $ 9.0111%28922
PRIMECAP Management 2011-03-31 Add 44.81%0.02%$6.75 - $11.02 $ 9.015%6202000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 7.09
ARAY's P/B is ranked lower than
67% of the 355 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. ARAY: 7.09 )
ARAY' s 10-Year P/B Range
Min: 1.1   Max: 11.5
Current: 7.09

1.1
11.5
P/S 2.07
ARAY's P/S is ranked higher than
65% of the 378 Companies
in the Global Medical Devices industry.

( Industry Median: 2.80 vs. ARAY: 2.07 )
ARAY' s 10-Year P/S Range
Min: 0.81   Max: 5.99
Current: 2.07

0.81
5.99
EV-to-EBIT -14.37
ARAY's EV-to-EBIT is ranked lower than
74% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 20.80 vs. ARAY: -14.37 )
ARAY' s 10-Year EV-to-EBIT Range
Min: 34.1   Max: 802.9
Current: -14.37

34.1
802.9

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 69.30
ARAY's Price/Tangible Book is ranked lower than
88% of the 326 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. ARAY: 69.30 )
ARAY' s 10-Year Price/Tangible Book Range
Min: 1.97   Max: 82
Current: 69.3

1.97
82
Price/Median PS Value 1.18
ARAY's Price/Median PS Value is ranked higher than
62% of the 334 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. ARAY: 1.18 )
ARAY' s 10-Year Price/Median PS Value Range
Min: 0.48   Max: 3.18
Current: 1.18

0.48
3.18
Earnings Yield (Greenblatt) 0.50
ARAY's Earnings Yield (Greenblatt) is ranked lower than
65% of the 279 Companies
in the Global Medical Devices industry.

( Industry Median: 4.50 vs. ARAY: 0.50 )
ARAY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 2.9
Current: 0.5

0.1
2.9
Forward Rate of Return (Yacktman) -1.85
ARAY's Forward Rate of Return (Yacktman) is ranked higher than
69% of the 261 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. ARAY: -1.85 )
ARAY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1   Max: 2.1
Current: -1.85

1
2.1

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:XEJ.Germany
Accuray, Inc., was incorporated in California in 1990 and commenced operations in 1992. The Company was reincorporated in 2007 in Delaware. The Company is a radiation oncology company. The Company's technologies are designed specifically to deliver precise radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, and image guided radiation therapy and adaptive radiation therapy tailored to the specific needs of each patient. Its suite of products includes the CyberKnife Systems and the TomoTherapy Systems. The CyberKnife Systems are fully robotic stereotactic radiosurgery systems, or SRS and stereotactic body radiation therapy systems, or SBRT used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimeter accuracy while patients breathe normally. Treatment with the CyberKnife Systems requires no anesthesia, and can be performed in one to five staged treatment sessions on an outpatient basis. In addition, the CyberKnife Systems are designed to minimize many of the risks and complications that are associated with other treatment options. The CyberKnife Systems include: the CyberKnife G4, which includes the Fixed collimator; CyberKnife VSI System, which includes the Fixed and Iris collimators and the new CyberKnife M6 Series System, that comes in configurations that have the option of Fixed collimator, Iris collimator, and a MultiLeaf collimator, or MLC. The TomoTherapy Systems are used to treat a wide range of cancers and tumors, and enable efficient daily imaging to ensure the accuracy of the patient position before each treatment delivery. The TomoTherapy Systems operate on ring gantries and combine integrated CT imaging with intensity modulated radiation therapy or IMRT, which is designed to deliver radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The TomoTherapy Systems include the Hi-Art System, delivering CT-guided, helical IMRT; the TomoHD System, which includes both the TomoHelicalTM and TomoDirectTM treatment modalities and the Tomo H TM Series Systems that come in configuration options of TomoHTM, TomoHD and TomoHDATM and which includes one or more options such as TomoHelicalTM, TomoDirectTM, High Performance VoLo TM Planning and TomoEdge Dynamic Jaws.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide